However, understanding the complex interplay between IL-17, IL-27, and IL-33—including the timing in which cytokine augmentation or blockade may potentially be beneficial—suggests this axis may potentially be manipulatable for therapeutic gain as part of a precision medicine approach toward sepsis treatment. This evidence concerns the gene IL27 and Sepsis.